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background: The optimal antithrombotic therapy after myocardial infarction for patients with atrial fibrillation is uncertain.
methods:  All patients with atrial fibrillation who had been hospitalized for myocardial infarction and undergone percutaneous coronary 
intervention (PCI) between July 2005 and December 2009 (n = 4324) were identified in SWEDEHEART, the national Swedish register for 
coronary disease, and linked with the National Drug Register, the National Patient Register and the Cause of Death Register. Commonly 
used antithrombotic regimens were compared using Cox regressions adjusted for factors in the CHA2DS2-VASc score, with regard to a 
1-year composite endpoint of death, reinfarction and ischemic stroke. A secondary endpoint was all bleedings requiring hospitalization.
Results:  At discharge, 625 (14.5%) patients were prescribed single antiplatelet therapy, 102 (2.4%) warfarin monotherapy, 2721 (62.9%) 
dual antiplatelet therapy, 435 (10.1%) warfarin + single antiplatelet and 441 (10.2%) triple therapy (warfarin + two antiplatelet agents). 
Outcomes are presented in the figure.
conclusion:  In patients with atrial fibrillation and myocardial infarction undergoing PCI, as compared to dual antiplatelet therapy, treatment 
with warfarin + single antiplatelet agent was associated with lower 1-year risk of death, reinfarction and ischemic stroke. Triple therapy was 
associated with an almost doubled risk of bleeding without reduction in death, reinfarction and ischemic stroke.
